Elon knows the truth, which is why they want him silenced

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.

Watch this new documentary and you’ll discover what Elon knows,

Lawrence Hineline Biography and Net Worth

CFO of Intra-Cellular Therapies

Mr. Hineline has served as Chief Financial Officer and Secretary of ITCI since June 2002. From December 2000 to November 2003, Mr. Hineline was the Vice-President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and as Corporate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a start-up and was later acquired by Baxter Health Care.

Mr. Hineline is a licensed CPA in the State of Maryland and received his Bachelor’s Degree from the University of Maryland Baltimore County.

What is Lawrence J. Hineline's net worth?: The estimated net worth of Lawrence J. Hineline is at least $864,284.34 as of February 19th, 2021. Mr. Hineline owns 10,442 shares of Intra-Cellular Therapies stock worth more than $864,284 as of November 18th. This net worth approximation does not reflect any other assets that Mr. Hineline may own. Learn More about Lawrence J. Hineline's net worth.
How do I contact Lawrence J. Hineline?: The corporate mailing address for Mr. Hineline and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected]. Learn More on Lawrence J. Hineline's contact information.
Has Lawrence J. Hineline been buying or selling shares of Intra-Cellular Therapies?: Lawrence J. Hineline has not been actively trading shares of Intra-Cellular Therapies within the last three months. Most recently, Lawrence J. Hineline sold 10,121 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.96, for a transaction totalling $667,581.16. Learn More on Lawrence J. Hineline's trading history.
Who are Intra-Cellular Therapies' active insiders?: Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), Rory Riggs (Director), and Robert Van Nostrand (Director). Learn More on Intra-Cellular Therapies' active insiders.
Are insiders buying or selling shares of Intra-Cellular Therapies?: During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 667,956 shares worth more than $46,911,949.27. The most recent insider tranaction occured on November, 12th when President Michael Halstead sold 22,869 shares worth more than $2,038,085.28. Insiders at Intra-Cellular Therapies own 2.6% of the company. Learn More about insider trades at Intra-Cellular Therapies.
Information on this page was last updated on 11/12/2024.

Lawrence J. Hineline Insider Trading History at Intra-Cellular Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	10,121	$65.96	$667,581.16
3/7/2024	Sell	13,132	$66.60	$874,591.20	29,700
2/26/2024	Sell	13,337	$69.43	$925,987.91
6/14/2023	Sell	81,854	$63.97	$5,236,200.38
3/13/2023	Sell	5,582	$44.93	$250,799.26
3/10/2023	Sell	15,663	$43.06	$674,448.78
2/24/2023	Sell	7,455	$47.03	$350,608.65
2/21/2023	Sell	10,443	$46.82	$488,941.26
2/17/2023	Sell	53,968	$49.83	$2,689,225.44
9/21/2022	Sell	65,164	$45.63	$2,973,433.32
2/24/2022	Sell	7,454	$51.97	$387,384.38
2/22/2022	Sell	10,443	$55.40	$578,542.20
1/10/2022	Sell	19,639	$40.76	$800,485.64
12/21/2021	Sell	175,000	$47.59	$8,328,250.00
2/19/2021	Sell	10,442	$39.23	$409,639.66	10,442
1/11/2021	Sell	19,638	$32.02	$628,808.76
1/4/2021	Sell	15,810	$31.31	$495,011.10
11/11/2020	Sell	28,034	$25.41	$712,343.94	18,034
9/9/2020	Sell	41,983	$31.14	$1,307,350.62	50,017
1/9/2020	Sell	19,638	$26.16	$513,730.08	18,800
2/27/2019	Sell	1,000	$15.00	$15,000.00	25,832
1/2/2019	Sell	7,807	$11.09	$86,579.63	24,839
2/16/2018	Sell	49,700	$20.02	$994,994.00
1/4/2018	Sell	3,192	$15.67	$50,018.64	68,686
1/5/2017	Sell	1,918	$16.58	$31,800.44	63,389
12/15/2015	Sell	45,000	$51.45	$2,315,250.00	62,200
11/24/2015	Sell	5,000	$55.00	$275,000.00	59,700
12/9/2014	Sell	22,500	$16.71	$375,975.00
9/8/2014	Sell	300	$15.00	$4,500.00

Lawrence J. Hineline Buying and Selling Activity at Intra-Cellular Therapies

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $82.77

$82.77

$83.61

50 Day Range

MA: $78.27

$71.19

$91.57

2 Week Range

Now: $82.77

$56.83

$93.45

Volume

21,914 shs

Average Volume

860,293 shs

Market Capitalization

$8.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97